Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
关注Panbela Therapeutics；Roth MKM说：“'益普生食品药品管理局批准Onivyde用于胰腺癌，而Panbela早些时候针对相同适应症的Sbp-101的1/1b期业绩使投资者有理由感到乐观。”重申买入和25美元的目标价”
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"
关注Panbela Therapeutics；Roth MKM说：“'益普生食品药品管理局批准Onivyde用于胰腺癌，而Panbela早些时候针对相同适应症的Sbp-101的1/1b期业绩使投资者有理由感到乐观。”重申买入和25美元的目标价”
资讯热榜
更新时间